NCT01976338 - Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) | Biotech Hunter

Enrollment

283

Participants

Timeline

Start Date

November 12, 2013

Primary Completion Date

March 28, 2016

Study Completion Date

March 28, 2016

Conditions

Macular Edema Secondary to Branch Retinal Vein Occlusion

Interventions

DRUG

Ranibizumab 0.5 mg

intravitreal injection of 0.05 ml

OTHER

Sham injection

Sham intravitreal injection

Trial Locations (33)

1000

Novartis Investigative Site, Manila

1500

Novartis Investigative Site, San Juan City

10000

Novartis Investigative Site, Hanoi

10430

Novartis Investigative Site, Jakarta

33305

Novartis Investigative Site, Linkou District

40117

Novartis Investigative Site, Bandung

70000

Novartis Investigative Site, Ho Chi Minh City

83301

Novartis Investigative Site, Kaohsiung City

100034

Novartis Investigative Site, Beijing

100176

Novartis Investigative Site, Beijing

100191

Novartis Investigative Site, Beijing

100730

Novartis Investigative Site, Beijing

150001

Novartis Investigative Site, Harbin

200080

Novartis Investigative Site, Shanghai

200092

Novartis Investigative Site, Shanghai

210006

Novartis Investigative Site, Nanjing

210029

Novartis Investigative Site, Nanjing

226000

Novartis Investigative Site, Nantong

266011

Novartis Investigative Site, Qingdao

300020

Novartis Investigative Site, Tianjin

300070

Novartis Investigative Site, Tianjin

325027

Novartis Investigative Site, Wenzhou

330006

Novartis Investigative Site, Nanchang

400038

Novartis Investigative Site, Chongqing

400042

Novartis Investigative Site, Chongqing

410011

Novartis Investigative Site, Changsha

430070

Novartis Investigative Site, Wuhan

510060

Novartis Investigative Site, Guangzhou

515041

Novartis Investigative Site, Shantou

610041

Novartis Investigative Site, Chengdu

Unknown

Novartis Investigative Site, Hong Kong

Novartis Investigative Site, Taipei